Inmed announces results of 2024 annual general meeting

Vancouver, british columbia--(newsfile corp. - december 18, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general meeting of shareholders held on december 18, 2024 (the "meeting"), the matters put forward before shareholders for consideration and approval as set out in inmed's notice of meeting and management information circular, dated october 28, 2024, were voted upon by the shareholders. a total of 5,318,677 common shares of the company, representing approximately 39.83% of the company's 13,353,431 issued and outstanding common shares, were represented in person or by proxy at the meeting.
GM Ratings Summary
GM Quant Ranking